Researchers said at the ESMO 16th Globe Congress on Gastrointestinal Malignancy in Barcelona.

There have been 3 treatment arms: MM-398, regular treatment with 5-fluorouracil /leucovorin, and MM-398 plus 5FU/leucovorin. The trial included 417 patients who had progressed or received gemcitabine-based therapy prior. The primary endpoint was general survival. General survival was significantly improved with the combination therapy of MM-398 plus 5FU/leucovorin compared to 5FU/leucovorin alone. Median general survival was 6.1 months in the MM-398 plus 5FU/leucovorin group in comparison to 4.2 months in the group receiving standard treatment with 5FU/leucovorin alone .ABAXIS approves repurchase of $40,000,000 of common stock ABAXIS, Inc. today announced that its Panel of Directors has authorized the repurchase of up to an aggregate of $40,000,000 of its Common Share.6 billion reduction to NIH budget Proposed cuts to the National Institutes of Health cover 2011 will certainly limit the nation’s capability to advance patient care and community health. Position: The American Society of Nephrology strongly opposes the proposed $1.6 billion reduction to the NIH budget included in the continuing resolution being debated in the House of Representatives.